Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion

BENGALURU, India — Bristol Myers Squibb announced on Friday that it will acquire the privately-held cell therapy developer Orbital Therapeutics for $1.5 billion in cash. This acquisition aims to enhance Bristol’s portfolio of CAR T-cell therapies, which are designed to treat various medical conditions.

Orbital’s leading experimental product, OTX-201, specifically targets autoimmune diseases. The CAR-T therapy works by genetically modifying a patient’s own immune cells to help them identify and attack disease-causing cells more effectively.

“With the acquisition of Orbital Therapeutics, we have an incredible opportunity to make CAR T-cell therapy more efficient and accessible to more patients,” said Lynelle B. Hoch, president of the Cell Therapy Organization at Bristol Myers.

This deal marks a significant step for Bristol Myers Squibb in expanding its capabilities in the field of cell therapy, addressing the growing demand for innovative treatments that harness the body’s immune system.

Bristol Myers Squibb continues to focus on enhancing patient care through advanced therapies while supporting research and development in the medical community.